Drug Type Small molecule drug |
Synonyms Acoradine, 淫羊藿素, 淫羊藿素软胶囊 + [4] |
Target |
Action inhibitors, antagonists |
Mechanism BHLHE40 inhibitors(basic helix-loop-helix family member e40 inhibitors), ERα antagonists(Estrogen receptor alpha antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (10 Jan 2022), |
RegulationConditional marketing approval (China), Priority Review (China) |
Molecular FormulaC21H20O6 |
InChIKeyTUUXBSASAQJECY-UHFFFAOYSA-N |
CAS Registry118525-40-9 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Unresectable Hepatocellular Carcinoma | China | 10 Jan 2022 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Hepatocellular Carcinoma | Phase 3 | China | 08 Sep 2017 | |
| Hepatitis B Virus-Related Hepatocellular Carcinoma | Phase 3 | China | 08 Sep 2017 | |
| Neoplasms | Phase 1 | China | 30 Jan 2022 | |
| Advanced cancer | Phase 1 | China | 28 Nov 2011 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 01 Nov 2011 | |
| Advanced breast cancer | Phase 1 | China | 01 Nov 2010 | |
| Metastatic breast cancer | Phase 1 | China | 01 Nov 2010 | |
| Advanced Pancreatic Ductal Adenocarcinoma | Clinical | China | - | |
| Pancreatic Cancer | IND Approval | China | 19 Sep 2025 | |
| Microsatellite instability-high colorectal cancer | IND Approval | China | 04 Mar 2025 |
Phase 3 | 283 | iypqugydlo(cnewsjtxhy) = nzyaagndeg vixlegzjii (vrohvldnzd ) View more | Positive | 20 May 2021 | |||
huachashu | iypqugydlo(cnewsjtxhy) = doxlapzwgi vixlegzjii (vrohvldnzd ) View more | ||||||
Phase 1 | 20 | dibtwbwgee(xhwfnmeegn) = fhnirurqgg eobtlvndjb (nprlslgjqa ) View more | Positive | 28 Mar 2019 |





